SOAN - AngioSoma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0008
+0.0001 (+14.29%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0007
Open0.0008
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0006 - 0.0008
52 Week Range0.0006 - 0.0209
Volume11,111,666
Avg. Volume12,051,120
Market Cap255,551
Beta (5Y Monthly)-2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    AngioSoma's Development of Atherectomy Catheter

    Houston, TX, May 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company’s peripheral arterial disease (“PAD”) product, Atherectomy Catheter II, is a catheter-based platform capable of treating a broad range of plaque types, including calcified plaque and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. This device uses a camera that allows physicians to better control treatment of PAD patients. In addition, the Atherectomy Catheter II includes a vacuum mechanism that extracts any removed plaque from the arteries and from the patient.

  • GlobeNewswire

    AngioSoma Continues to Liquidate Debt

    Houston, TX, April 21, 2020 -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) today announced that holders of the Company's 12% unsecured.

  • GlobeNewswire

    AngioSoma Moving Forward With Exciting New Products

    Houston, TX, March 09, 2020 -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) today announced creating an innovative marketing strategy for its.

  • GlobeNewswire

    AngioSoma Announces Trademark Allowed for Muscles4U

    Houston, TX, Jan. 22, 2020 -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that we have received official notice of.

  • GlobeNewswire

    AngioSoma Acquires Technology Related to 15 Patents

    Houston, Jan. 15, 2020 -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that we have acquired the unconditional ownership.

  • GlobeNewswire

    Litigation Settlement Agreement Finished

    Houston, TX, Jan. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) founding Director and Chief Executive Officer, Alex Blankenship, announced closing of the settlement agreement to conclude the 2-year legal dispute between founder David Summers and AngioSoma. The parties agreed that the legal expense is a substantial incentive to terminate the dispute. Closing of the previously signed settlement agreement was signed by both parties on January 9, 2020.

  • GlobeNewswire

    AngioSoma Explains History of Muscles4U.com

    When I found my first of two grandchildren was on the way, I decided body building was too intense, so I changed to routine workouts at the gym to stay fit and healthy. To make my workout more effective and productive, I tried several supplements that were advertised to enhance workouts.

  • GlobeNewswire

    AngioSoma Developing Male Enhancement Supplement

    HOUSTON, TX, Jan. 06, 2020 -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) today announced development of Full Salute™, a male ED (erectile.

  • GlobeNewswire

    AngioSoma Reacquires $11,600,000 Series A Preferred

    The Series of Preferred Stock is nonvoting and has priority in liquidation over the shares of common stock. Reacquisition and cancellation of the Preferred Stock eliminates any obligation to redeem the Preferred Stock and eliminates AngioSoma’s annual cumulative dividend obligation in the amount of $928,000. “The successful reacquisition and cancellation of all the outstanding Series A Preferred Stock has strengthened our balance sheet and effectively left AngioSoma with no accrued cumulative dividends,” said Alex Blankenship, CEO of AngioSoma.

  • GlobeNewswire

    AngioSoma has Repaid $469,000 of Notes

    Houston, TX, Nov. 20, 2019 -- via NEWMEDIAWIRE --AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) today announced that holders of the Company's 12% unsecured.

  • GlobeNewswire

    AngioSoma, Inc. Announces Settlement of Litigation 

    Houston, Texas, Oct. 22, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) is pleased to announce the Company has executed a Settlement Agreement of the litigation with.

  • GlobeNewswire

    AngioSoma Confirms Status of Voting Control

    Houston, TX , Aug. 20, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company has filed an amendment to its Form 10-K for the fiscal year ended.